{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:17:36Z","timestamp":1793737056806,"version":"4.6.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82573892"],"award-info":[{"award-number":["82573892"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372633"],"award-info":[{"award-number":["82372633"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02679-6","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:27:28Z","timestamp":1779960448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting MORC2 activates transposable element-mediated viral mimicry and potentiates immune checkpoint blockade in triple-negative breast cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Fang-Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Andriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Min","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Yong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2679_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348.","journal-title":"N Engl J Med"},{"key":"2679_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrclinonc.2010.154","volume":"7","author":"L Carey","year":"2010","unstructured":"Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683\u201392.","journal-title":"Nat Rev Clin Oncol"},{"key":"2679_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2679_CR4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090\u2013100.","journal-title":"Lancet"},{"key":"2679_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im SA, Shaw Wright G, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"2679_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328.","journal-title":"Lancet"},{"key":"2679_CR7","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med"},{"key":"2679_CR8","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, Denkert C, Park YH, Hui R, Harbeck N, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024;391:1981\u201391.","journal-title":"N Engl J Med"},{"key":"2679_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jama.2024.23560","volume":"333","author":"L Chen","year":"2025","unstructured":"Chen L, Li H, Zhang H, Yang H, Qian J, Li Z, Ren Y, Wang S, Fu P, Yang H, et al. Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial. JAMA. 2025;333:673\u201381.","journal-title":"JAMA"},{"key":"2679_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","volume":"30","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, Wang H, Yin Y, Wang X, Zhou X, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024;30:249\u201356.","journal-title":"Nat Med"},{"key":"2679_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-018-0126-6","volume":"119","author":"L Wein","year":"2018","unstructured":"Wein L, Luen SJ, Savas P, Salgado R, Loi S. Checkpoint blockade in the treatment of breast cancer: current status and future directions. Br J Cancer. 2018;119:4\u201311.","journal-title":"Br J Cancer"},{"key":"2679_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22:145.","journal-title":"Mol Cancer"},{"key":"2679_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nrm.2017.26","volume":"18","author":"CR Clapier","year":"2017","unstructured":"Clapier CR, Iwasa J, Cairns BR, Peterson CL. Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes. Nat Rev Mol Cell Biol. 2017;18:407\u201322.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2679_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41576-018-0089-8","volume":"20","author":"SL Klemm","year":"2019","unstructured":"Klemm SL, Shipony Z, Greenleaf WJ. Chromatin accessibility and the regulatory epigenome. Nat Rev Genet. 2019;20:207\u201320.","journal-title":"Nat Rev Genet"},{"key":"2679_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrm.2017.113","volume":"19","author":"I Marazzi","year":"2018","unstructured":"Marazzi I, Greenbaum BD, Low DHP, Guccione E. Chromatin dependencies in cancer and inflammation. Nat Rev Mol Cell Biol. 2018;19:245\u201361.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2679_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41580-023-00683-y","volume":"25","author":"S Eustermann","year":"2024","unstructured":"Eustermann S, Patel AB, Hopfner KP, He Y, Korber P. Energy-driven genome regulation by ATP-dependent chromatin remodellers. Nat Rev Mol Cell Biol. 2024;25:309\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2679_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","volume":"17","author":"P Mittal","year":"2020","unstructured":"Mittal P, Roberts CWM. The SWI\/SNF complex in cancer - biology, biomarkers and therapy. Nat Rev Clin Oncol. 2020;17:435\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"2679_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41573-024-00978-5","volume":"23","author":"HA Malone","year":"2024","unstructured":"Malone HA, Roberts CWM. Chromatin remodellers as therapeutic targets. Nat Rev Drug Discov. 2024;23:661\u201381.","journal-title":"Nat Rev Drug Discov"},{"key":"2679_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, Valencia AM, Shifrut E, Kale N, Yost KE, et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell. 2022;40:768\u2013e786767.","journal-title":"Cancer Cell"},{"key":"2679_CR20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.molcel.2023.02.026","volume":"83","author":"E Battistello","year":"2023","unstructured":"Battistello E, Hixon KA, Comstock DE, Collings CK, Chen X, Rodriguez Hernaez J, Lee S, Cervantes KS, Hinkley MM, Ntatsoulis K, et al. Stepwise activities of mSWI\/SNF family chromatin remodeling complexes direct T cell activation and exhaustion. Mol Cell. 2023;83:1216\u2013e12361212.","journal-title":"Mol Cell"},{"key":"2679_CR21","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.immuni.2023.05.008","volume":"56","author":"AE Baxter","year":"2023","unstructured":"Baxter AE, Huang H, Giles JR, Chen Z, Wu JE, Drury S, Dalton K, Park SL, Torres L, Simone BW, et al. The SWI\/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8(+) T cells. Immunity. 2023;56:1320\u2013e13401310.","journal-title":"Immunity"},{"key":"2679_CR22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359:770\u20135.","journal-title":"Science"},{"key":"2679_CR23","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1158\/0008-5472.CAN-24-2054","volume":"85","author":"Y Wang","year":"2025","unstructured":"Wang Y, Meraz IM, Qudratullah M, Kotagiri S, Han Y, Xi Y, Wang J, Akdemir KC, Roth JA, Lissanu Y. Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. Cancer Res. 2025;85:1997\u20132013.","journal-title":"Cancer Res"},{"key":"2679_CR24","doi-asserted-by":"publisher","first-page":"eabk0957","DOI":"10.1126\/sciimmunol.abk0957","volume":"7","author":"K Itahashi","year":"2022","unstructured":"Itahashi K, Irie T, Yuda J, Kumagai S, Tanegashima T, Lin YT, Watanabe S, Goto Y, Suzuki J, Aokage K, et al. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci Immunol. 2022;7:eabk0957.","journal-title":"Sci Immunol"},{"key":"2679_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4161\/epi.24976","volume":"8","author":"DQ Li","year":"2013","unstructured":"Li DQ, Nair SS, Kumar R. The MORC family: new epigenetic regulators of transcription and DNA damage response. Epigenetics. 2013;8:685\u201393.","journal-title":"Epigenetics"},{"key":"2679_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.tibs.2003.09.007","volume":"28","author":"J Perry","year":"2003","unstructured":"Perry J, Zhao Y. The CW domain, a structural module shared amongst vertebrates, vertebrate-infecting parasites and higher plants. Trends Biochem Sci. 2003;28:576\u201380.","journal-title":"Trends Biochem Sci"},{"key":"2679_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1745-6150-3-8","volume":"3","author":"LM Iyer","year":"2008","unstructured":"Iyer LM, Abhiman S, Aravind L. MutL homologs in restriction-modification systems and the origin of eukaryotic MORC ATPases. Biol Direct. 2008;3:8.","journal-title":"Biol Direct"},{"key":"2679_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12964-019-0477-5","volume":"17","author":"HY Xie","year":"2019","unstructured":"Xie HY, Zhang TM, Hu SY, Shao ZM, Li DQ. Dimerization of MORC2 through its C-terminal coiled-coil domain enhances chromatin dynamics and promotes DNA repair. Cell Commun Signal. 2019;17:160.","journal-title":"Cell Commun Signal"},{"key":"2679_CR29","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.celrep.2012.11.018","volume":"2","author":"DQ Li","year":"2012","unstructured":"Li DQ, Nair SS, Ohshiro K, Kumar A, Nair VS, Pakala SB, Reddy SD, Gajula RP, Eswaran J, Aravind L, Kumar R. MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled chromatin remodeling during the DNA damage response. Cell Rep. 2012;2:1657\u201369.","journal-title":"Cell Rep"},{"key":"2679_CR30","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41467-025-60751-z","volume":"16","author":"W Tan","year":"2025","unstructured":"Tan W, Park J, Venugopal H, Lou J, Dias PS, Baldoni PL, Moon KW, Dite TA, Keenan CR, Gurzau AD, et al. MORC2 is a phosphorylation-dependent DNA compaction machine. Nat Commun. 2025;16:5606.","journal-title":"Nat Commun"},{"key":"2679_CR31","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/ng.3878","volume":"49","author":"IA Tchasovnikarova","year":"2017","unstructured":"Tchasovnikarova IA, Timms RT, Douse CH, Roberts RC, Dougan G, Kingston RE, Modis Y, Lehner PJ. Hyperactivation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2. Nat Genet. 2017;49:1035\u201344.","journal-title":"Nat Genet"},{"key":"2679_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nature25179","volume":"553","author":"N Liu","year":"2018","unstructured":"Liu N, Lee CH, Swigut T, Grow E, Gu B, Bassik MC, Wysocka J. Selective silencing of euchromatic L1s revealed by genome-wide screens for L1 regulators. Nature. 2018;553:228\u201332.","journal-title":"Nature"},{"key":"2679_CR33","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41418-021-00901-0","volume":"29","author":"YY Liu","year":"2022","unstructured":"Liu YY, Liu HY, Yu TJ, Lu Q, Zhang FL, Liu GY, Shao ZM, Li DQ. O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-\u03b2 signaling to breast cancer progression. Cell Death Differ. 2022;29:861\u201373.","journal-title":"Cell Death Differ"},{"key":"2679_CR34","doi-asserted-by":"publisher","first-page":"973","DOI":"10.7150\/thno.79688","volume":"13","author":"FL Zhang","year":"2023","unstructured":"Zhang FL, Yang SY, Liao L, Zhang TM, Zhang YL, Hu SY, Deng L, Huang MY, Andriani L, Ma XY, et al. Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer. Theranostics. 2023;13:973\u201390.","journal-title":"Theranostics"},{"key":"2679_CR35","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1093\/nar\/gkaa130","volume":"48","author":"HY Liu","year":"2020","unstructured":"Liu HY, Liu YY, Yang F, Zhang L, Zhang FL, Hu X, Shao ZM, Li DQ. Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic Acids Res. 2020;48:3638\u201356.","journal-title":"Nucleic Acids Res"},{"key":"2679_CR36","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1093\/nar\/gkz545","volume":"47","author":"L Zhang","year":"2019","unstructured":"Zhang L, Li DQ. MORC2 regulates DNA damage response through a PARP1-dependent pathway. Nucleic Acids Res. 2019;47:8502\u201320.","journal-title":"Nucleic Acids Res"},{"key":"2679_CR37","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/15548627.2019.1659609","volume":"16","author":"F Yang","year":"2020","unstructured":"Yang F, Xie HY, Yang LF, Zhang L, Zhang FL, Liu HY, Li DQ, Shao ZM. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells. Autophagy. 2020;16:1061\u201376.","journal-title":"Autophagy"},{"key":"2679_CR38","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1158\/0008-5472.CAN-17-1394","volume":"78","author":"FL Zhang","year":"2018","unstructured":"Zhang FL, Cao JL, Xie HY, Sun R, Yang LF, Shao ZM, Li DQ. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer. Cancer Res. 2018;78:5780\u201392.","journal-title":"Cancer Res"},{"key":"2679_CR39","doi-asserted-by":"publisher","first-page":"e1210","DOI":"10.1002\/ctm2.1210","volume":"13","author":"SY Hu","year":"2023","unstructured":"Hu SY, Qian JX, Yang SY, Andriani L, Liao L, Deng L, Huang MY, Zhang YL, Zhang FL, Shao ZM, Li DQ. Destabilization of microrchidia family CW-type zinc finger 2 via the cyclin-dependent kinase 1-chaperone-mediated autophagy pathway promotes mitotic arrest and enhances cancer cellular sensitivity to microtubule-targeting agents. Clin Transl Med. 2023;13:e1210.","journal-title":"Clin Transl Med"},{"key":"2679_CR40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s43018-024-00725-0","volume":"5","author":"YZ Jiang","year":"2024","unstructured":"Jiang YZ, Ma D, Jin X, Xiao Y, Yu Y, Shi J, Zhou YF, Fu T, Lin CJ, Dai LJ, et al. Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nat Cancer. 2024;5:673\u201390.","journal-title":"Nat Cancer"},{"key":"2679_CR41","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35:428\u2013e440425.","journal-title":"Cancer Cell"},{"key":"2679_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Comprehensive molecular","year":"2012","unstructured":"Comprehensive molecular. portraits of human breast tumours. Nature. 2012;490:61\u201370.","journal-title":"Nature"},{"key":"2679_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346\u201352.","journal-title":"Nature"},{"key":"2679_CR44","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.ccell.2023.06.009","volume":"41","author":"Y Li","year":"2023","unstructured":"Li Y, Dou Y, Da Veiga Leprevost F, Geffen Y, Calinawan AP, Aguet F, Akiyama Y, Anand S, Birger C, Cao S, et al. Proteogenomic data and resources for pan-cancer analysis. Cancer Cell. 2023;41:1397\u2013406.","journal-title":"Cancer Cell"},{"key":"2679_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2022.04.006","volume":"120","author":"X Wang","year":"2022","unstructured":"Wang X, Wei J, Zhu R, Chen L, Ding F, Zhou R, Ge L, Xiao J, Zhao Q. Contribution of CD4\u2009+\u2009T cell-mediated inflammation to diarrhea in patients with COVID-19. Int J Infect Dis. 2022;120:1\u201311.","journal-title":"Int J Infect Dis"},{"key":"2679_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"2679_CR47","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1093\/bioinformatics\/btv422","volume":"31","author":"Y Jin","year":"2015","unstructured":"Jin Y, Tam OH, Paniagua E, Hammell M. TEtranscripts: a package for including transposable elements in differential expression analysis of RNA-seq datasets. Bioinformatics. 2015;31:3593\u20139.","journal-title":"Bioinformatics"},{"key":"2679_CR48","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"2679_CR49","doi-asserted-by":"crossref","unstructured":"Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG, Ginhoux F, Newell EW. Dimensionality reduction for visualizing single-cell data using UMAP. Nat Biotechnol. 2019;37:38\u201344.","DOI":"10.1038\/nbt.4314"},{"key":"2679_CR50","doi-asserted-by":"publisher","first-page":"100166","DOI":"10.1016\/j.mocell.2024.100166","volume":"48","author":"X Zhao","year":"2025","unstructured":"Zhao X, Miao J. Biological functions and molecular mechanisms of MORC2 in human diseases. Mol Cells. 2025;48:100166.","journal-title":"Mol Cells"},{"key":"2679_CR51","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/jcp.25665","volume":"232","author":"G Hong","year":"2017","unstructured":"Hong G, Qiu H, Wang C, Jadhav G, Wang H, Tickner J, He W, Xu J. The Emerging Role of MORC Family Proteins in Cancer Development and Bone Homeostasis. J Cell Physiol. 2017;232:928\u201334.","journal-title":"J Cell Physiol"},{"key":"2679_CR52","doi-asserted-by":"publisher","first-page":"896854","DOI":"10.3389\/fncel.2022.896854","volume":"16","author":"A Jacquier","year":"2022","unstructured":"Jacquier A, Roubille S, Lomonte P, Schaeffer L. Microrchidia CW-Type Zinc Finger 2, a Chromatin Modifier in a Spectrum of Peripheral Neuropathies. Front Cell Neurosci. 2022;16:896854.","journal-title":"Front Cell Neurosci"},{"key":"2679_CR53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","volume":"595","author":"GK Griffin","year":"2021","unstructured":"Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, Dele-Oni D, Du PP, Halawi AG, Ishizuka JJ, et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021;595:309\u201314.","journal-title":"Nature"},{"key":"2679_CR54","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1158\/2326-6066.CIR-22-0249","volume":"10","author":"M Yang","year":"2022","unstructured":"Yang M, Miao YR, Xie GY, Luo M, Hu H, Kwok HF, Feng J, Guo AY. ICBatlas: A Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics from Transcriptome Profiles. Cancer Immunol Res. 2022;10:1398\u2013406.","journal-title":"Cancer Immunol Res"},{"key":"2679_CR55","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, Park K, Esteller M, Lee SH, Choi JK. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019;10:4278.","journal-title":"Nat Commun"},{"key":"2679_CR56","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449\u201358.","journal-title":"Nat Med"},{"key":"2679_CR57","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019;35:238\u2013e255236.","journal-title":"Cancer Cell"},{"key":"2679_CR58","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/hmg\/8.7.1201","volume":"8","author":"N Inoue","year":"1999","unstructured":"Inoue N, Hess KD, Moreadith RW, Richardson LL, Handel MA, Watson ML, Zinn AR. New gene family defined by MORC, a nuclear protein required for mouse spermatogenesis. Hum Mol Genet. 1999;8:1201\u20137.","journal-title":"Hum Mol Genet"},{"key":"2679_CR59","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","volume":"31","author":"YZ Jiang","year":"2021","unstructured":"Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021;31:178\u201386.","journal-title":"Cell Res"},{"key":"2679_CR60","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019;37:559\u201369.","journal-title":"J Clin Oncol"},{"key":"2679_CR61","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","volume":"32","author":"S Loi","year":"2021","unstructured":"Loi S, Michiels S, Adams S, Loibl S, Budczies J, Denkert C, Salgado R. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32:1236\u201344.","journal-title":"Ann Oncol"},{"key":"2679_CR62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41523-023-00541-2","volume":"9","author":"DB Page","year":"2023","unstructured":"Page DB, Pucilowska J, Chun B, Kim I, Sanchez K, Moxon N, Mellinger S, Wu Y, Koguchi Y, Conrad V, et al. A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st\/2nd line metastatic triple-negative breast cancer. NPJ Breast Cancer. 2023;9:53.","journal-title":"NPJ Breast Cancer"},{"key":"2679_CR63","doi-asserted-by":"crossref","unstructured":"Gandhi S, Slomba RT, Janes C, Fitzpatrick V, Miller J, Attwood K, Ioannou G, Ozbey S, De Souza I, Roudko V et al. Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Immunother Cancer. 2024;12:e010058.","DOI":"10.1136\/jitc-2024-010058"},{"key":"2679_CR64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1078-0432.CCR-23-1349","volume":"30","author":"AD Wilkerson","year":"2024","unstructured":"Wilkerson AD, Parthasarathy PB, Stabellini N, Mitchell C, Pavicic PG Jr., Fu P, Rupani A, Husic H, Rayman PA, Swaidani S, et al. Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2024;30:82\u201393.","journal-title":"Clin Cancer Res"},{"key":"2679_CR65","doi-asserted-by":"publisher","first-page":"eadj7808","DOI":"10.1126\/scitranslmed.adj7808","volume":"17","author":"T Fu","year":"2025","unstructured":"Fu T, Jin X, He M, Chen YY, Yang YS, Chen L, Zhang HY, Fan L, Wu J, Wang ZH, et al. Interferon-induced senescent CD8(+) T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer. Sci Transl Med. 2025;17:eadj7808.","journal-title":"Sci Transl Med"},{"key":"2679_CR66","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","volume":"179","author":"DP Hollern","year":"2019","unstructured":"Hollern DP, Xu N, Thennavan A, Glodowski C, Garcia-Recio S, Mott KR, He X, Garay JP, Carey-Ewend K, Marron D, et al. B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. Cell. 2019;179:1191\u2013e12061121.","journal-title":"Cell"},{"key":"2679_CR67","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13058-023-01676-7","volume":"25","author":"C Zheng","year":"2023","unstructured":"Zheng C, Xu X, Wu M, Xue L, Zhu J, Xia H, Ding S, Fu S, Wang X, Wang Y, et al. Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance. Breast Cancer Res. 2023;25:88.","journal-title":"Breast Cancer Res"},{"key":"2679_CR68","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nri3073","volume":"11","author":"PJ Murray","year":"2011","unstructured":"Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11:723\u201337.","journal-title":"Nat Rev Immunol"},{"key":"2679_CR69","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nri3088","volume":"11","author":"T Lawrence","year":"2011","unstructured":"Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11:750\u201361.","journal-title":"Nat Rev Immunol"},{"key":"2679_CR70","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23:295\u2013316.","journal-title":"Nat Rev Cancer"},{"key":"2679_CR71","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48\u201361.","journal-title":"Cell"},{"key":"2679_CR72","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","volume":"6","author":"GP Dunn","year":"2006","unstructured":"Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836\u201348.","journal-title":"Nat Rev Immunol"},{"key":"2679_CR73","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","volume":"79","author":"R Yu","year":"2022","unstructured":"Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. 2022;79:191.","journal-title":"Cell Mol Life Sci"},{"key":"2679_CR74","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00262-010-0956-4","volume":"60","author":"C Domschke","year":"2011","unstructured":"Domschke C, Schuetz F, Ge Y, Rom J, Zorn M, Sinn HP, Marme F, Schott S, Heil J, Scharf A, et al. Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha\/IL-12 in breast cancer patients. Cancer Immunol Immunother. 2011;60:401\u201311.","journal-title":"Cancer Immunol Immunother"},{"key":"2679_CR75","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1158\/2159-8290.CD-21-0506","volume":"11","author":"R Chen","year":"2021","unstructured":"Chen R, Ishak CA, De Carvalho DD. Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis. Cancer Discov. 2021;11:2707\u201325.","journal-title":"Cancer Discov"},{"key":"2679_CR76","doi-asserted-by":"publisher","first-page":"eado8758","DOI":"10.1126\/sciimmunol.ado8758","volume":"9","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhang Y, Li M, Ming T, Zhang C, Huang C, Li J, Li F, Li H, Zhao E, et al. Oncogenic KRAS drives immunosuppression of colorectal cancer by impairing DDX60-mediated dsRNA accumulation and viral mimicry. Sci Immunol. 2024;9:eado8758.","journal-title":"Sci Immunol"},{"key":"2679_CR77","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41467-018-03045-x","volume":"9","author":"CH Douse","year":"2018","unstructured":"Douse CH, Bloor S, Liu Y, Shamin M, Tchasovnikarova IA, Timms RT, Lehner PJ, Modis Y. Neuropathic MORC2 mutations perturb GHKL ATPase dimerization dynamics and epigenetic silencing by multiple structural mechanisms. Nat Commun. 2018;9:651.","journal-title":"Nat Commun"},{"key":"2679_CR78","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.molcel.2024.05.004","volume":"84","author":"R Zheng","year":"2024","unstructured":"Zheng R, Dunlap M, Bobkov GOM, Gonzalez-Figueroa C, Patel KJ, Lyu J, Harvey SE, Chan TW, Quinones-Valdez G, Choudhury M, et al. hnRNPM protects against the dsRNA-mediated interferon response by repressing LINE-associated cryptic splicing. Mol Cell. 2024;84:2087\u2013103. e2088.","journal-title":"Mol Cell"},{"key":"2679_CR79","doi-asserted-by":"publisher","first-page":"eadl6173","DOI":"10.1126\/science.adl6173","volume":"385","author":"MJ Wu","year":"2024","unstructured":"Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, et al. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024;385:eadl6173.","journal-title":"Science"},{"key":"2679_CR80","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nri.2016.27","volume":"16","author":"G Kassiotis","year":"2016","unstructured":"Kassiotis G, Stoye JP. Immune responses to endogenous retroelements: taking the bad with the good. Nat Rev Immunol. 2016;16:207\u201319.","journal-title":"Nat Rev Immunol"},{"key":"2679_CR81","doi-asserted-by":"crossref","unstructured":"Tu Y, Zhu QY, Huang WJ, Feng S, Tan YL, Li LL, Xie XT, Li QY, Huang SH, Mao CZ et al. DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I\/MDA5-MAVS to enhance antitumor immunity. Acta Pharmacol Sin. 2026;47:197\u2013208.","DOI":"10.1038\/s41401-025-01639-y"},{"key":"2679_CR82","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19:136.","journal-title":"Mol Cancer"},{"key":"2679_CR83","first-page":"71","volume":"3","author":"B Lamontagne","year":"2001","unstructured":"Lamontagne B, Larose S, Boulanger J, Elela SA. The RNase III family: a conserved structure and expanding functions in eukaryotic dsRNA metabolism. Curr Issues Mol Biol. 2001;3:71\u20138.","journal-title":"Curr Issues Mol Biol"},{"key":"2679_CR84","doi-asserted-by":"crossref","unstructured":"Vall\u00e9s-Saiz L, \u00c1vila J, Hern\u00e1ndez F. Lamivudine (3TC), a Nucleoside Reverse Transcriptase Inhibitor, Prevents the Neuropathological Alterations Present in Mutant Tau Transgenic Mice. Int J Mol Sci. 2023;24:11144.","DOI":"10.3390\/ijms241311144"},{"key":"2679_CR85","doi-asserted-by":"crossref","unstructured":"Oleksiewicz U, Kuciak M, Jaworska A, Adamczak D, Bisok A, Mierzejewska J, Sadowska J, Czerwinska P, Mackiewicz AA. The Roles of H3K9me3 Writers, Readers, and Erasers in Cancer Immunotherapy. Int J Mol Sci. 2024;25:11466.","DOI":"10.3390\/ijms252111466"},{"key":"2679_CR86","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.stem.2011.04.004","volume":"8","author":"MM Karimi","year":"2011","unstructured":"Karimi MM, Goyal P, Maksakova IA, Bilenky M, Leung D, Tang JX, Shinkai Y, Mager DL, Jones S, Hirst M, Lorincz MC. DNA methylation and SETDB1\/H3K9me3 regulate predominantly distinct sets of genes, retroelements, and chimeric transcripts in mESCs. Cell Stem Cell. 2011;8:676\u201387.","journal-title":"Cell Stem Cell"},{"key":"2679_CR87","doi-asserted-by":"crossref","unstructured":"Fendler NL, Ly J, Welp L, Lu D, Schulte F, Urlaub H, Vos SM. Identification and characterization of a human MORC2 DNA binding region that is required for gene silencing. Nucleic Acids Res. 2025;53:gkae1273.","DOI":"10.1093\/nar\/gkae1273"},{"key":"2679_CR88","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1126\/science.1221472","volume":"336","author":"G Moissiard","year":"2012","unstructured":"Moissiard G, Cokus SJ, Cary J, Feng S, Billi AC, Stroud H, Husmann D, Zhan Y, Lajoie BR, McCord RP, et al. MORC family ATPases required for heterochromatin condensation and gene silencing. Science. 2012;336:1448\u201351.","journal-title":"Science"},{"key":"2679_CR89","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.str.2010.06.012","volume":"18","author":"F He","year":"2010","unstructured":"He F, Umehara T, Saito K, Harada T, Watanabe S, Yabuki T, Kigawa T, Takahashi M, Kuwasako K, Tsuda K, et al. Structural insight into the zinc finger CW domain as a histone modification reader. Structure. 2010;18:1127\u201339.","journal-title":"Structure"},{"key":"2679_CR90","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1038\/emboj.2011.108","volume":"30","author":"V Hoppmann","year":"2011","unstructured":"Hoppmann V, Thorstensen T, Kristiansen PE, Veiseth SV, Rahman MA, Finne K, Aalen RB, Aasland R. The CW domain, a new histone recognition module in chromatin proteins. Embo j. 2011;30:1939\u201352.","journal-title":"Embo j"},{"key":"2679_CR91","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1038\/s41598-018-24467-z","volume":"8","author":"G Kaur","year":"2018","unstructured":"Kaur G, Iyer LM, Subramanian S, Aravind L. Evolutionary convergence and divergence in archaeal chromosomal proteins and Chromo-like domains from bacteria and eukaryotes. Sci Rep. 2018;8:6196.","journal-title":"Sci Rep"},{"key":"2679_CR92","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/B978-0-12-387685-0.00004-4","volume":"101","author":"L Aravind","year":"2011","unstructured":"Aravind L, Abhiman S, Iyer LM. Natural history of the eukaryotic chromatin protein methylation system. Prog Mol Biol Transl Sci. 2011;101:105\u201376.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2679_CR93","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1016\/j.bmc.2019.07.020","volume":"27","author":"P Mader","year":"2019","unstructured":"Mader P, Mendoza-Sanchez R, Iqbal A, Dong A, Dobrovetsky E, Corless VB, Liew SK, Houliston SR, De Freitas RF, Smil D, et al. Identification and characterization of the first fragment hits for SETDB1 Tudor domain. Bioorg Med Chem. 2019;27:3866\u201378.","journal-title":"Bioorg Med Chem"},{"key":"2679_CR94","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1101\/gad.973302","volume":"16","author":"DC Schultz","year":"2002","unstructured":"Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ. 3rd: SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 2002;16:919\u201332.","journal-title":"Genes Dev"},{"key":"2679_CR95","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41556-018-0266-1","volume":"21","author":"G Wang","year":"2019","unstructured":"Wang G, Long J, Gao Y, Zhang W, Han F, Xu C, Sun L, Yang SC, Lan J, Hou Z, et al. SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. Nat Cell Biol. 2019;21:214\u201325.","journal-title":"Nat Cell Biol"},{"key":"2679_CR96","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41556-018-0261-6","volume":"21","author":"J Guo","year":"2019","unstructured":"Guo J, Dai X, Laurent B, Zheng N, Gan W, Zhang J, Guo A, Yuan M, Liu P, Asara JM, et al. AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions. Nat Cell Biol. 2019;21:226\u201337.","journal-title":"Nat Cell Biol"},{"key":"2679_CR97","doi-asserted-by":"publisher","first-page":"8651","DOI":"10.1038\/ncomms9651","volume":"6","author":"Q Fei","year":"2015","unstructured":"Fei Q, Shang K, Zhang J, Chuai S, Kong D, Zhou T, Fu S, Liang Y, Li C, Chen Z, et al. Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53. Nat Commun. 2015;6:8651.","journal-title":"Nat Commun"},{"key":"2679_CR98","doi-asserted-by":"publisher","first-page":"114536","DOI":"10.1016\/j.celrep.2024.114536","volume":"43","author":"YH Chang","year":"2024","unstructured":"Chang YH, Yamamoto K, Fujino T, Wang TW, Sugimoto E, Zhang W, Yabushita T, Suzaki K, Pietsch EC, Weir BA, et al. SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. Cell Rep. 2024;43:114536.","journal-title":"Cell Rep"},{"key":"2679_CR99","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.cell.2024.12.013","volume":"188","author":"ME Oomen","year":"2025","unstructured":"Oomen ME, Rodriguez-Terrones D, Kurome M, Zakhartchenko V, Mottes L, Simmet K, Noll C, Nakatani T, Mourra-Diaz CM, Aksoy I, et al. An atlas of transcription initiation reveals regulatory principles of gene and transposable element expression in early mammalian development. Cell. 2025;188:1156\u2013e11741120.","journal-title":"Cell"},{"key":"2679_CR100","doi-asserted-by":"publisher","first-page":"1020490","DOI":"10.3389\/fcell.2022.1020490","volume":"10","author":"C Li","year":"2022","unstructured":"Li C, Zhang Y, Leng L, Pan X, Zhao D, Li X, Huang J, Bolund L, Lin G, Luo Y, Xu F. The single-cell expression profile of transposable elements and transcription factors in human early biparental and uniparental embryonic development. Front Cell Dev Biol. 2022;10:1020490.","journal-title":"Front Cell Dev Biol"},{"key":"2679_CR101","doi-asserted-by":"crossref","unstructured":"Geis FK, Goff SP. Silencing and Transcriptional Regulation of Endogenous Retroviruses: An Overview. Viruses. 2020;12:884.","DOI":"10.3390\/v12080884"},{"key":"2679_CR102","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature08674","volume":"463","author":"HM Rowe","year":"2010","unstructured":"Rowe HM, Jakobsson J, Mesnard D, Rougemont J, Reynard S, Aktas T, Maillard PV, Layard-Liesching H, Verp S, Marquis J, et al. KAP1 controls endogenous retroviruses in embryonic stem cells. Nature. 2010;463:237\u201340.","journal-title":"Nature"},{"key":"2679_CR103","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1002\/ctm2.825","volume":"12","author":"F Yang","year":"2022","unstructured":"Yang F, Sun R, Hou Z, Zhang FL, Xiao Y, Yang YS, Yang SY, Xie YF, Liu YY, Luo C, et al. HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression. Clin Transl Med. 2022;12:e825.","journal-title":"Clin Transl Med"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02679-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:07:11Z","timestamp":1785521231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02679-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2679"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02679-6","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"184"}}